Tailoring Treatment for Myelofibrosis: Advancements in Molecular Profiling and Individualized Approaches
-
By
-
Rafal Al-Shibly
-
Rasha Kaddoura
-
Omar Ismail
-
Mohamed A. Yassin
-
July 15, 2026
Clinical Scorecard: Tailoring Treatment for Myelofibrosis: Advancements in Molecular Profiling and Individualized Approaches
At a Glance
| Category | Detail |
|---|
| Condition | Myelofibrosis |
| Key Mechanisms | JAK-STAT signaling, inflammatory marrow remodeling, cytopenias, extramedullary hematopoiesis |
| Target Population | Patients with primary and secondary myelofibrosis |
| Care Setting | Precision medicine in hematology |
Key Highlights
- Myelofibrosis is biologically heterogeneous, requiring integrated assessment for treatment.
- Ruxolitinib is the first-line treatment for symptomatic proliferative disease.
- Allogeneic hematopoietic cell transplantation is the only curative strategy.
- Emerging AI applications may enhance precision care but require validation.
- Diagnosis should guide precision management rather than serve as a static label.
Guideline-Based Recommendations
Diagnosis
- Utilize bone marrow morphology and driver mutation testing for accurate diagnosis.
Management
- Select JAK inhibitors based on phenotype and symptom burden.
Monitoring & Follow-up
- Conduct structured symptom assessments and risk evaluations regularly.
Risks
- Acknowledge the risk of leukemic transformation and treatment resistance.
Patient & Prescribing Data
Individuals with primary and secondary myelofibrosis
Treatment should be tailored based on molecular profile and symptomatology.
Clinical Best Practices
- Differentiate between primary and secondary myelofibrosis in treatment planning.
- Discuss allogeneic transplantation early for high-risk patients.
- Implement dynamic prognostic modeling in clinical decision-making.
Related Resources & Content
